<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105546</url>
  </required_header>
  <id_info>
    <org_study_id>ENJOIH 01</org_study_id>
    <secondary_id>IND 14503</secondary_id>
    <nct_id>NCT01105546</nct_id>
  </id_info>
  <brief_title>rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors</brief_title>
  <acronym>ENJOIH</acronym>
  <official_title>An Investigator-initiated Study on rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors - European Initiative to Prevent Joint Damage in Hemophilia A Children With Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the efficacy and safety of a prophylactic treatment with recombinant
      activated FVII in reducing the frequency of joint bleeds and the development of joint damage
      in children with hemophilia A who develop high-titer inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, randomised, controlled study designed to gain evidence of the
      advantage of the prophylactic, daily treatment with recombinant activated FVII as compared to
      the conventional on demand therapy in reducing the bleeding frequency and preserving the
      orthopaedic status in hemophilic children with inhibitors.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of joint bleeds.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Joint status evaluated by the Hemophilia Joint Health Score</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and serious adverse events.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hemophilia A With Inhibitors</condition>
  <arm_group>
    <arm_group_label>prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prophylaxis with recombinant activated FVII 90 µg/kg/day i.v.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>on demand treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant activated factor VII</intervention_name>
    <description>90 µg/kg/day i.v.</description>
    <arm_group_label>prophylaxis</arm_group_label>
    <other_name>NovoSeven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant activated factor VII</intervention_name>
    <description>treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution</description>
    <arm_group_label>on demand treatment</arm_group_label>
    <other_name>NovoSeven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hemophilia A who have been treated with factor VIII on demand or on
             prophylaxis and who have developed inhibitors to factor VIII

          -  ≤ 2 years from the time of first inhibitor detection.

          -  High-responding inhibitors (historical peak &gt; 5 BU/mL)and known anamnestic response in
             case of negative inhibitor titre.

          -  Candidates to start daily ITI with FVIII doses ranging from 50 IU/Kg/day to 200
             IU/Kg/day

          -  Maximal two bleedings in the same joint within the last 6 months before entering the
             study or maximal six joint bleeds in the same joint within 2 years

          -  Adequate venous access for daily infusion and capable (caregiver) of reconstituting
             and injecting the study drug

          -  Informed consent by parents or legal guardians.

        Exclusion Criteria:

          -  ITI already started

          -  Known or suspected hypersensitivity to the active substance or to any of the
             excipients of the study drug

          -  Administration of any investigational product within 30 days prior to randomisation

          -  Other coagulation disorders than congenital hemophilia A.

          -  Family history of thrombosis at an early age (&lt; 40 years), known thrombophilia, any
             previous thrombosis including catheter-related deep vein thrombosis, previous neonatal
             thrombosis.

          -  Known pseudo tumours

          -  Known severe liver disease

          -  Platelet count &lt; 50,000 platelets/µL at screening

          -  Surgery within one month or planned major and/or orthopaedic surgery.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Santagostino, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemophilia Comprehensive Care Centre, Edouard Herriot University Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain Haemophilia Care Center, Medical Center</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik</name>
      <address>
        <city>Bremen</city>
        <zip>28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universitat</name>
      <address>
        <city>Frankfurt/M</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi Agenzia per l'emofilia e Centro di riferimento regionale per i disordini congeniti del sanguinamento</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Emofilia e Trombosi Unità Operativa di Ematologia Ospedale San Giovanni Bosco</name>
      <address>
        <city>Napoli</city>
        <zip>80144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute for Transfusional Hematology</name>
      <address>
        <city>Bucarest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitaluc Clinic de Urgenta pentru Copii Louis Turcanu, University of Medicine and Pharmacy</name>
      <address>
        <city>Timisoara</city>
        <zip>300011</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unitat Hemofilia, Hospital Vall d'Hebron</name>
      <address>
        <city>Barcellona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Hemofilia, Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Coagulopatias Congenitas, Hospital Universitario la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</investigator_affiliation>
    <investigator_full_name>Elena Santagostino</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>hemophilia A</keyword>
  <keyword>inhibitors</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>immune tolerance induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

